Bio-Gene Technology Limited (ASX:BGT)
Australia · Delayed Price · Currency is AUD 0.0170
0.00 (0.00%)
Jul 15, 2026, 9:59 AM AEST
Bio-Gene Technology Market Cap
Bio-Gene Technology has a market cap or net worth of 6.56 million as of July 14, 2026. Its market cap has decreased by -1.23% in one year.
Market Cap
6.56M
Enterprise Value
5.48M
Revenue
n/a
Ranking
n/a
PE Ratio
n/a
Stock Price
0.02
Market Cap Chart
Since November 29, 2017, Bio-Gene Technology's market cap has decreased from 20.89M to 6.56M, a decrease of -68.58%. That is a compound annual growth rate of -12.56%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 14, 2026 | 6.56M | -6.46% |
| Dec 29, 2025 | 7.02M | -18.97% |
| Dec 30, 2024 | 8.66M | -28.33% |
| Dec 29, 2023 | 12.08M | -32.09% |
| Dec 29, 2022 | 17.79M | -48.81% |
| Dec 31, 2021 | 34.76M | 61.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Nov 29, 2017 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| ReNerve | 13.78M |
| AdAlta | 11.90M |
| Cambium Bio | 11.07M |
| Vectus Biosystems | 10.76M |
| Invex Therapeutics | 7.89M |
| Tissue Repair | 6.65M |
| Zelira Therapeutics | 5.95M |
| Acrux | 5.65M |